tradingkey.logo
tradingkey.logo
Search

Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma

ReutersSep 23, 2025 11:05 AM
facebooktwitterlinkedin

- Bristol-Myers Squibb Co BMY.N:

  • BRISTOL MYERS SQUIBB ANNOUNCES PHASE 3 EXCALIBER-RRMM STUDY EVALUATING IBERDOMIDE IN COMBINATION WITH STANDARD THERAPIES DEMONSTRATED A SIGNIFICANT IMPROVEMENT IN MINIMAL RESIDUAL DISEASE NEGATIVITY RATES IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA

  • BRISTOL-MYERS SQUIBB CO - SAFETY PROFILE OF IBERDOMIDE COMBINATION CONSISTENT WITH PREVIOUS STUDIES

  • BRISTOL-MYERS SQUIBB CO - IBERDOMIDE WITH STANDARD THERAPIES IMPROVES MRD NEGATIVITY RATES

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI